GI Cell - About the company
GI Cell is a funded company based in Seongnam-si (South Korea), founded in 2019. It operates as a Developer of immune cell-based therapeutics for multiple diseases. The company has 3848 active competitors, including 1304 funded and 894 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.
Company Details
Developer of immune cell-based therapeutics for multiple diseases. The company provides Tumor-targeting Optimally Primed (TOP) NK Cell therapies for solid tumors, Drone Treg Cell therapy for an inflammatory bowel disorder, and GI-COV-VAX for covid-19.
- Website
- gi-cell.com
- Email ID
- *****@gi-cell.com
Key Metrics
Founded Year
2019
Location
Seongnam-si, South Korea
Stage
Funding Raised
Investors
Ranked
2684th among 3848 active competitors
Similar Companies
Legal entities associated with GI Cell
GI Cell is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
GIcell Co., Ltd. CIN: 250-81-01224 , South Korea, Active | Oct 17, 2018 | - | - | - |
Sign up to download GI Cell's company profile
GI Cell's funding and investors
GI Cell is a funded company. GI Cell has 1 institutional investor.
View details of GI Cell's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
GI Cell's Competitors and alternates
Top competitors of GI Cell include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of GI Cell, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 73/100 | |
7th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
8th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 72/100 | |
9th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
10th | Dynavax 1996, Berkeley (United States), Acquired | Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $73.9M | 72/100 | |
2684th |  GI Cell 2019, Seongnam-si (South Korea), Funding Raised | Developer of immune cell-based therapeutics for multiple diseases | - | 25/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on GI Cell's competitors? Click here to see the top ones
GI Cell's Investments and acquisitions
GI Cell has made no investments or acquisitions yet.
Reports related to GI Cell
Here is the latest report on GI Cell's sector:
News related to GI Cell
Filter this list•
•
•
•
•
GI Cell Enters Agreement with Optieum BiotechnologiesACROFAN•Dec 12, 2022•GI Cell, Optieum Biotechnologies
•
•
•
GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapyBusiness Wire•Aug 29, 2022•GI Cell, HK Innoen
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about GI Cell
Explore our recently published companies
- Dl-Dental-2000 - Germany based, Unfunded company
- Kardiokl - Germany based, Unfunded company
- Blk-Care - Unfunded company
- DRPU Software - Ghaziabad based, 2008 founded, Public company
- Independent School District 625 - United States based, Funding Raised company
- Scioto Valley Solar One - Columbus based, 2021 founded, Funding Raised company
